使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day, and welcome to the Bausch Health Third Quarter 2019 Earnings Conference Call. (Operator Instructions) Please note, this event is being recorded. I would now like to turn the conference over to Art Shannon, Senior Vice President, Head of Investor Relations and Corporate Communications. Please go ahead.
各位好,歡迎參加 Bausch Health 2019 年第三季財報電話會議。(接線員指示) 請注意,本活動將被錄音。現在我想把會議交給投資人關係與企業傳播部資深副總裁兼主管 Art Shannon。請開始。
Arthur J. Shannon - Senior VP and Head of IR & Communications
Arthur J. Shannon - Senior VP and Head of IR & Communications
Thank you, Andrew. Good morning, everyone, and welcome to our third quarter 2019 financial results conference call. Participating on today's call are Chairman and Chief Executive Officer, Joe Papa; and Chief Financial Officer, Paul Herendeen. In addition to this live webcast, a copy of today's slide presentation and a replay of this conference call will be available on our website under the Investor Relations section.
謝謝你,Andrew。各位早安,歡迎參加我們 2019 年第三季財務業績電話會議。今天參與電話會議的有董事長兼執行長 Joe Papa,以及財務長 Paul Herendeen。除本次即時網路直播外,今日簡報投影片的副本與本次電話會議的重播,將可於我們網站「投資人關係」專區取得。
Before we begin, we'd like to remind you that our presentation today contains forward-looking information. We would ask that you take a moment to read the forward-looking statement legend at the beginning of our presentation as it contains important information.
在開始之前,我們提醒各位,今天的簡報包含前瞻性資訊。請各位花一點時間閱讀簡報開頭的前瞻性聲明說明,因其包含重要資訊。
This presentation contains non-GAAP financial measures. For more information about these measures, please refer to Slide 2 of the presentation. Non-GAAP reconciliations can be found in the appendix to the presentation posted on our website.
本簡報包含非 GAAP 財務衡量指標。關於這些衡量指標的更多資訊,請參閱簡報第 2 頁投影片。非 GAAP 調節表可於我們網站所發布之簡報附錄中查閱。
Finally, the financial guidance in this presentation is effective as of today only. It is our policy to generally not update guidance until the following quarter and not to update or affirm guidance other than through broadly disseminated public disclosure.
最後,本簡報中的財務指引僅於今日起生效。我們的政策通常是在下一季之前不更新指引,且除透過廣泛發布的公開揭露外,不更新或確認指引。
With that, it is my pleasure to turn the call over to Joe.
接下來,我很高興把電話會議交給 Joe。
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
Thank you, Art, and thank you, everyone, for joining us today. I'll begin with the third quarter highlights before turning the call over to Paul Herendeen, our CFO, to review the financial results in detail and update our 2019 guidance.
謝謝你,Art,也謝謝各位今天加入我們。我將先說明第三季重點,接著把電話交給我們的財務長 Paul Herendeen,由他詳細回顧財務結果並更新我們 2019 年的指引。
We'll then review the segment highlights and open the line for questions. Beginning with Slide 4, we had another strong quarter of sustained performance that demonstrates that our team is continuing to gain traction with our plan to pivot to offense.
之後我們將回顧各事業部門重點,並開放提問。從第 4 頁投影片開始,我們又交出一個強勁的季度、展現持續的表現,證明我們的團隊正持續在「轉守為攻」的計畫上取得進展。
Total company organic revenue grew by 4% compared to the third quarter of 2018 and represented the seventh consecutive quarter of total company organic revenue growth.
公司整體有機營收較 2018 年第三季成長 4%,並且是公司整體有機營收連續第七個季度成長。
P&L is leading our turnaround with a 12th consecutive quarter of organic revenue growth. Key drivers were a strong LUMIFY launch, strong international prescription results and the performance of our Global Vision Care business.
P&L 正帶領我們的轉型,達成有機營收連續第十二個季度成長。主要驅動因素包括 LUMIFY 上市表現強勁、國際處方業務成果亮眼,以及我們全球視力照護業務的表現。
Salix reported more than $500 million in total quarterly revenue, driven by XIFAXAN's 24% growth. Additionally, we generated $515 million of cash from operations and increased R&D investment by 15% during the third quarter.
Salix 單季總營收超過 5 億美元,主要由 XIFAXAN 成長 24% 所帶動。此外,我們第三季營運活動產生 5.15 億美元現金,並將研發投資提高 15%。
As of September 30, we have utilized approximately $900 million to repay approximately $700 million of debt and approximately $200 million to complete the acquisition of TRULANCE and enter into a license agreement for amiselimod.
截至 9 月 30 日,我們已動用約 9 億美元,用於償還約 7 億美元債務,以及約 2 億美元用於完成 TRULANCE 的收購並簽訂 amiselimod 的授權協議。
And in October, we acquired rights to XIPERE. I'll talk more about that later. Moving over to the right of Slide 4. Our new products are also producing results. The Thermage brand is now a top 10 Bausch Health franchise, following the successful launch of Thermage FLX in the Asia Pacific region.
而在 10 月,我們取得了 XIPERE 的權利。我稍後會再多談一些。接著看第 4 頁投影片右側,我們的新產品也正在產生成果。Thermage 品牌在 Thermage FLX 於亞太地區成功上市後,現已成為 Bausch Health 前十大產品系列之一。
LUMIFY generated $21 million of revenue in the third quarter and has achieved a weekly market share of approximately 43%. TRULANCE generated $37 million of revenue since our synergy acquisition and continues to track the full year guidance of $55 million.
LUMIFY 第三季創造 2,100 萬美元營收,並已達到約 43% 的每週市占率。TRULANCE 自我們協同收購以來已創造 3,700 萬美元營收,且仍符合全年 5,500 萬美元的指引進度。
DUOBRII is off to a strong start at 4 months post launch, with weekly TRx tracking right around the 2,300 level. Thanks to a great team effort and the continued engagement of over 21,000 employees of Bausch Health, we have delivered another strong quarter. We remain focused on launching new products, improving operations and delivering on the commitments we outlined at the beginning of the year.
DUOBRII 上市後第 4 個月即有強勁開局,每週 TRx 約維持在 2,300 左右。憑藉優秀的團隊努力,以及 Bausch Health 超過 21,000 名員工的持續投入,我們又交出一個強勁的季度。我們仍專注於推出新產品、改善營運,並履行我們在年初所提出的承諾。
With that, I'll turn it over to Paul.
接下來交給 Paul。
Paul S. Herendeen - Executive VP & CFO
Paul S. Herendeen - Executive VP & CFO
Yes. Thanks, Joe. And I'll start with a quick walk down the Q3 P&L, which is on Slide 5. First, some housekeeping. When we talk about organic growth, we mean on a constant currency basis and adjusted to remove the impact of acquisitions and divestitures. So top line organic revenue growth of 4% in the quarter. As Joe said, the seventh consecutive quarter of organic revenue growth. Pretty good considering we absorbed the growth drag of $85 million from LOE assets versus Q3 of 2018.
好的。謝謝,Joe。我先快速帶各位走一遍第三季損益表(P&L),在第 5 頁投影片。先做幾點說明。當我們談到有機成長時,是指以固定匯率計算,並調整以排除併購與資產處分的影響。因此,本季營收端(top line)有機成長 4%。如 Joe 所說,這是連續第七個季度的有機營收成長。考量到相較 2018 年第三季,我們吸收了來自 LOE 資產 8,500 萬美元的成長拖累,這表現相當不錯。
Revenue in our B+ L/International segment grew 5% organically in the quarter. Four of the five subsegments within B + L posted growth, led by the Global Consumer business, up 7% organically in large part on the continued ramp from LUMIFY, followed by our International Rx business, up 7% organically on strength in Canada, Russia, and the Middle East. Next, our Global Vision Care business was up 10% in the U.S. and 4% outside the United States, plus 6% overall on strength in our Biotrue ONEday lens family, our Ultra monthly silicone hydrogel lenses and the ramp of AQUALOX, our daily silicone hydrogel lenses in Japan.
我們的 B+L/International 事業部門本季有機成長 5%。B + L 的五個子事業中有四個呈現成長,其中以全球消費者業務領先,有機成長 7%,主要來自 LUMIFY 持續放量;其次是國際處方(International Rx)業務,有機成長 7%,受惠於加拿大、俄羅斯與中東的強勁表現。接著,我們的全球視力照護(Global Vision Care)業務在美國成長 10%、在美國以外成長 4%,合計整體成長 6%,主要受惠於 Biotrue ONEday 鏡片系列、Ultra 月拋矽水膠鏡片,以及 AQUALOX(我們在日本的日拋矽水膠鏡片)放量成長。
Next, Global Surgical was up 5% organically on strength from our Stellaris Elite system and related consumables. And finally, to wrap up the B + L segment from a revenue perspective, Global Ophtho Rx declined 6% organically, mainly due to the greater erosion of our branded Lotemax business in the U.S., including revenue lost to our own authorized generic of Lotemax Suspension that shows up in our generics business in our Diversified segment.
接著,全球手術(Global Surgical)業務有機成長 5%,主要受惠於 Stellaris Elite 系統及相關耗材的強勁表現。最後,從營收角度總結 B + L 事業部門,全球眼科處方(Global Ophtho Rx)有機下滑 6%,主要因美國 Lotemax 品牌業務侵蝕加劇,包括因我們自家 Lotemax Suspension 授權學名藥而流失的營收;該授權學名藥的營收則計入我們多元化(Diversified)事業部門的學名藥業務中。
So overall, a solid quarter for the B+ L/International segment. Salix delivered another terrific quarter, up 18% organically, which excludes the $14 million of TRULANCE revenue in the quarter. The star again was XIFAXAN, as Joe said, up 24% versus Q3 of 2018. But I want to break down the components of that 24% as it's important in how you think about growth rates for XIFAXAN in Q4 and into 2020.
因此整體而言,B+L/International 事業部門本季表現穩健。Salix 再次交出非常出色的一季,有機成長 18%,此數字不包含本季 1,400 萬美元的 TRULANCE 營收。如 Joe 所說,明星產品仍是 XIFAXAN,較 2018 年第三季成長 24%。但我想拆解這 24% 的組成,因為這對你們思考 XIFAXAN 在第四季以及進入 2020 年的成長率很重要。
So the 24% growth versus Q3 2018 came 8% from volume, meaning more units sold, 6% from the net impact of the price increase that we took for XIFAXAN back in January, and the balance of the plus 10% came as a result of successful initiatives that we implemented as part of our Project CORE to improve gross to nets with XIFAXAN.
因此,相較 2018 年第三季的 24% 成長,其中 8% 來自銷量(volume),也就是賣出更多單位;6% 來自我們在 1 月對 XIFAXAN 調價所帶來的價格上調淨影響;其餘約 +10% 則來自我們在 Project CORE 中所推動並成功落地的各項措施,以改善 XIFAXAN 的 gross-to-nets。
Reminder, CORE stands for Cost Optimization and Revenue Enhancement. This clearly falls into the revenue enhancement category. From a growth perspective, roughly half of the Project CORE driven growth in XIFAXAN in 2019 is durable and will continue on in future XIFAXAN results. So think of it as a step function increase in realized net selling prices for XIFAXAN.
提醒一下,CORE 代表成本最佳化與營收提升(Cost Optimization and Revenue Enhancement)。這很明顯屬於營收提升的範疇。從成長角度來看,2019 年由 Project CORE 驅動的 XIFAXAN 成長中,約有一半是具持續性的,並將延續到未來的 XIFAXAN 業績中。因此可將其視為 XIFAXAN 已實現淨售價的一次性階梯式上升。
While the other half is more transitory, very real value, driven by reductions in process gross to net items in 2019 results, but not repeating in 2020. I'll repeat what I've said in a number of public forums when thinking about XIFAXAN's growth prospects in 2020. Growth will be driven by a combination of volume, which is selling more units and perhaps a couple 100 basis points of net selling price increase if we raise the gross selling price.
而另一半則較為短暫,但確實具有真實價值,主要由 2019 年業績中流程端毛到淨(gross-to-net)項目的下降所驅動,但不會在 2020 年重複出現。在思考 XIFAXAN 於 2020 年的成長前景時,我會重申我在多個公開場合所說的話。成長將由銷量(也就是賣出更多單位)與淨售價的提升共同驅動;若我們提高毛售價,淨售價可能上升約數百個基點。
So important safety tip. While I would and you should expect XIFAXAN to deliver net sales growth at an attractive rate in 2020 versus '19, that growth will not be at the levels you're seeing in 2019. While I'm on the subject, I mentioned on our Q2 call that we expected about 1 more quarter that's this quarter, of strong performance from Glumetza before that brand sees more pronounced losses of revenue due to an accelerated shift in channel mix, resulting in substantial deterioration in net selling prices.
所以這裡有個重要的安全提示。雖然我會、你也應該預期 XIFAXAN 在 2020 年相較於 2019 年能以具吸引力的速度實現淨銷售成長,但該成長不會達到你在 2019 年看到的水準。順帶一提,我在我們第二季電話會議中提到,我們預期 Glumetza 還會有大約 1 個季度(也就是本季度)的強勁表現,之後該品牌將因通路組合加速轉移而出現更明顯的營收流失,導致淨售價大幅惡化。
So as you think about Glumetza, the Q4 run rate for the brand maybe half of what we've seen in the first 3 quarters of 2019. On more positive notes, RELISTOR and PLENVU delivered TRx growth in the quarter, and TRULANCE accounted for $14 million of revenue and remains on track to deliver $55 million of revenue we guided to for 2019.
因此在思考 Glumetza 時,該品牌第四季的運行水準(run rate)可能只有我們在 2019 年前三季所見的一半左右。較正面的部分是,RELISTOR 與 PLENVU 在本季度實現 TRx 成長,而 TRULANCE 貢獻了 1,400 萬美元營收,並仍按計畫達成我們對 2019 年所給予的 5,500 萬美元營收指引。
In the Ortho Derm segment, total segment revenue was down 16% organically, as growth in Solta could not overcome declines in our Medical Derm business. Global Solta delivered organic growth of 62% on continued strong demand for our Thermage FLX systems, which, in turn, feeds demand for the consumable FLX tips. Solta has been delivering robust growth, mainly in Asia Pac. And as we look ahead to 2020, we will be allocating more resources to Tom Hart and his team to enable Solta to pursue similar opportunities in other regions, particularly Western Europe.
在 Ortho Derm 部門,部門總營收有機下滑 16%,因為 Solta 的成長無法抵消我們 Medical Derm 業務的下滑。全球 Solta 在 Thermage FLX 系統持續強勁需求帶動下,有機成長 62%,而這也進一步帶動對可耗材 FLX 探頭(tips)的需求。Solta 一直呈現強勁成長,主要在亞太地區。展望 2020 年,我們將投入更多資源給 Tom Hart 及其團隊,使 Solta 能在其他地區追求類似機會,特別是西歐。
Our Medical Derm business was down $47 million versus Q3 of 2018, militated by the $43 million impact of LOEs for Elidel, Zovirax, Solodyn and Acanya. With the bulk of the impact of the LOEs for Medical Derm now reflected in our quarter results, I want to call out that our Medical Derm business will be rebased in Q4 2019 at roughly $85 million to $90 million of net sales per quarter and be poised to return to growth with a portfolio of promoted brands, including DUOBRII, BRYHALI, SILIQ, ALTRENO
我們的 Medical Derm 業務較 2018 年第三季減少 4,700 萬美元,主要受 Elidel、Zovirax、Solodyn 與 Acanya 專利到期(LOE)影響 4,300 萬美元所致。由於 Medical Derm 的 LOE 影響大多已反映在本季度業績中,我想特別指出:我們的 Medical Derm 業務將在 2019 年第四季以每季約 8,500 萬至 9,000 萬美元的淨銷售額重新定基(rebased),並可望憑藉一系列重點推廣品牌回到成長軌道,包括 DUOBRII、BRYHALI、SILIQ、ALTRENO
and Jublia, plus tail brands, including Targretin, Retin-A Micro, Elidel, ONEXTON, Clindagel and others.
以及 Jublia,另加上長尾品牌(tail brands),包括 Targretin、Retin-A Micro、Elidel、ONEXTON、Clindagel 等等。
Finally, our Diversified segment declined 5% organically, considering that LOE assets were an approximately 900 basis point drag versus Q3 of 2018. That's a pretty good quarter for Barb Purcell and her team. I want to call out a few highlights.
最後,我們的 Diversified 部門有機下滑 5%,其中 LOE 資產相較 2018 年第三季約造成 900 個基點的拖累。對 Barb Purcell 與她的團隊而言,這是一個相當不錯的季度。我想點出幾個亮點。
Our buproprion franchise in the neuro business, including Wellbutrin XL and Aplenzin, grew 12% versus Q3 of 2018, as a result of targeted and effective promotion in collaboration with our market access team, led by Bob Spurr.
我們神經科業務中的安非他酮(bupropion)產品組合(包括 Wellbutrin XL 與 Aplenzin)較 2018 年第三季成長 12%,這得益於與市場准入團隊(由 Bob Spurr 領導)合作所進行的精準且有效的推廣。
Our generics unit has been the beneficiary of the LOEs of many of our branded products, launching and selling authorized generic versions of those brands. Generic revenues were up 7% versus Q3 of 2018.
我們的學名藥事業部受惠於多項品牌產品的專利到期(LOE),推出並銷售這些品牌的授權學名藥版本。學名藥營收較 2018 年第三季成長 7%。
Now I've said this before, but here it comes again. We manage the diversified group to maximize the long-term cash flows from a basket of assets that are expected to decline over time.
我以前說過,但我再說一次。我們管理多元化事業群的方式,是要將一籃子預期會隨時間下滑的資產所帶來的長期現金流最大化。
Our objective is to slow that decline and, thereby, maximize the cash flow, and our team is doing a great job there. Down at the gross margin line, with a -- excuse me, blended gross margin of 73.6% in the quarter, we were plus 80 basis points versus Q3 of 2018.
我們的目標是放緩這種下滑,從而最大化現金流,而我們的團隊在這方面做得非常出色。在毛利率方面,本季度綜合毛利率為 73.6%——抱歉——相較 2018 年第三季提高 80 個基點。
Our core initiatives within the supply chain drove the majority of the 50 basis point positive variance in the B+ L/International segment and roughly half the 350 basis point improvement in Salix. Mix improved gross margins in Salix, decreased gross margins in the Ortho Derm segment with Solta making up a greater percentage of total sales, and decreased gross margin than Diversified where generics made up a greater percentage of segment revenues.
我們供應鏈中的核心措施推動了 B+L/International 部門 50 個基點正向差異的大部分,以及 Salix 約一半的 350 個基點改善。產品組合(mix)使 Salix 的毛利率改善;在 Ortho Derm 部門,因 Solta 占總銷售比重提高而使毛利率下降;而在 Diversified 部門,因學名藥占部門營收比重提高而使毛利率下降。
Note that we are guiding to a roughly 73% gross margin for the full year 2019. Our year-to-date gross margin was 73.2%. Selling, advertising and promotion expenses increased by $32 million compared with Q3 of 2018, unfavorable by 7% reported and 8% constant currency. Half of that unfavorable movement came from B+ L/International and was due to our deploying additional promotional resources to drive revenue growth, mainly in the Global Vision Care and the International Surgical businesses.
請注意,我們對 2019 全年的毛利率指引約為 73%。我們年初至今的毛利率為 73.2%。銷售、廣告與推廣費用較 2018 年第三季增加 3,200 萬美元,按報告口徑不利 7%,按固定匯率口徑不利 8%。其中一半的不利變動來自 B+L/International,原因是我們投入額外的推廣資源以推動營收成長,主要在全球視力照護與國際外科業務。
The $13 million increase in selling and advertising and promotion in Salix was mainly due to the addition of roughly 100 sales territories associated with the acquisition of TRULANCE.
Salix 的銷售與廣告及推廣費用增加 1,300 萬美元,主要是因收購 TRULANCE 而新增約 100 個銷售區域(sales territories)。
Company-wide G&A spending was up 5%, mainly due to increased investment building out our IT infrastructure. Our investment in our R&D increased $16 million compared with Q3 of 2018, as we continue the process of building the R&D organization and adding to our portfolio of development projects to enable us to sustain long-term organic growth for our businesses.
全公司層面的 G&A(一般及行政)支出增加 5%,主要因加大投資以建置我們的 IT 基礎設施。我們的研發(R&D)投資較 2018 年第三季增加 1,600 萬美元,因我們持續建置研發組織並擴充開發專案組合,以支持各業務的長期有機成長。
Our adjusted EBITDA of $942 million in the quarter was up 3% on a reported and 2% on a constant currency basis, compared with Q3 of 2018. Good quarter.
本季度調整後 EBITDA 為 9.42 億美元,較 2018 年第三季按報告口徑成長 3%,按固定匯率口徑成長 2%。表現不錯的一季。
So Slides 6, 7, 8 and 9 show additional details for the segments, I'm not going to dwell on them as I've covered the main items of note on each. So turn to Slide 10, cash flow summary. In the quarter, we generated $515 million of cash from operating activities. The amount, while down slightly from the amount in the prior year quarter keeps us well aligned to deliver between $1.5 billion and $1.6 billion of cash from operations in 2019. Year-to-date, our cash provided by operating activities is up $85 million from the prior year.
因此,第 6、7、8 與 9 張投影片提供了各部門的更多細節;我不打算多做停留,因為我已涵蓋各部門的主要重點。接著看第 10 張投影片:現金流摘要。本季度,我們由營運活動產生 5.15 億美元現金。該金額雖較去年同期略降,但仍使我們有充分把握在 2019 年達成 15 億至 16 億美元的營運現金流目標。年初至今,我們由營運活動提供的現金較去年同期增加 8,500 萬美元。
If you flip to Slide 11, the balance sheet summary. During the quarter, we repaid $303 million of our term loan debt and paid $150 million to reduce our revolving credit borrowings to 0 at September 30, 2019.
如果你翻到第 11 張投影片,資產負債表摘要。在本季度期間,我們償還了 3.03 億美元的定期貸款債務,並支付了 1.50 億美元,將循環信貸借款在 2019 年 9 月 30 日降至 0。
Year-to-date to September 30, we've repaid $631 million of long-term debt and reduced revolving credit borrowings by $75 million. I want to note that we could have repaid more long-term debt year-to-date, but elected to allocate roughly $200 million of cash flow to what we view as high-value business development activity, mainly in this case, the acquisition of TRULANCE.
截至 9 月 30 日的年初至今,我們已償還 6.31 億美元的長期債務,並將循環信貸借款減少 7,500 萬美元。我想指出的是,年初至今我們本可以償還更多長期債務,但我們選擇將約 2 億美元的現金流配置到我們認為具高價值的業務發展活動上,主要是在本案中收購 TRULANCE。
On to Slide 12 in our revised guidance. Today, we raised and tightened our full year 2019 guidance for revenue, increasing the low end of the range by $75 million, and the top end by $25 million. The new range is $8.475 billion to $8.625 billion. The midpoint of our current revenue guidance is up $50 million from our August guidance from the midpoint of the August guidance.
接著看第 12 張投影片,我們修訂後的指引。今天,我們上調並收緊了 2019 全年營收指引,將區間下限提高 7,500 萬美元、上限提高 2,500 萬美元。新的區間為 84.75 億美元至 86.25 億美元。我們目前營收指引的中點較 8 月指引的中點上調 5,000 萬美元。
As you'll see on the guidance bridge on Slide 13, the raise was in part driven by $40 million increase in the revenue expectations for our LOE assets, with the most significant change moving the anticipated LOE date for Preser to 1H '20 and $20 million increase in revenue for our base business. Offset in part by unfavorable movements in FX since August, which reduced our forecast by about $10 million.
如你在第 13 張投影片的指引橋接圖所見,此次上調部分是由於我們對 LOE 資產的營收預期增加 4,000 萬美元所帶動,其中最顯著的變化是將 Preser 的預計 LOE 日期移至 2020 年上半年,並且我們的基礎業務營收增加 2,000 萬美元。但部分被 8 月以來外匯(FX)不利變動所抵銷,該變動使我們的預測減少約 1,000 萬美元。
We also raised and tightened our guidance for adjusted EBITDA to $3.5 billion to $3.6 billion. The midpoint of our current guidance is up $50 million from our August guidance. $35 million came -- of that came from greater revenue expectations for the LOE assets, $5 million from FX, plus -- that's plus $5 million from FX, minus $25 million for the higher-than-expected investment in R&D and plus $35 million from a combination of the increased base business revenue, improved gross margins and other items.
我們也上調並收緊了調整後 EBITDA 指引至 35 億美元至 36 億美元。我們目前指引的中點較 8 月指引上調 5,000 萬美元。其中 3,500 萬美元來自——其中來自對 LOE 資產更高的營收預期,外匯(FX)貢獻正向 500 萬美元,減去因研發(R&D)投資高於預期的 2,500 萬美元,再加上 3,500 萬美元,該部分來自基礎業務營收增加、毛利率改善及其他項目的綜合影響。
Last thing before I turn it back to Joe. I think it's worth looking back at how we now expect to end 2019 compared with our guidance from back in February. At the midpoint of our initial guidance range, we expected revenue of $8.4 billion for 2019. Midpoint of our current guidance revenue was $8.55 billion, so plus $150 million. $85 million of the increase in revenue comes from roughly $60 million more expected revenue from the LOE assets, $55 million from the acquisition of TRULANCE and offset by $30 million of unfavorable movements in FX. So that explains the first $85 million. The remaining $65 million increase comes from both better performance in our base businesses and better gross to nets in some businesses, driven by Project CORE than we originally forecast.
在我把話交回給 Joe 之前的最後一點。我認為值得回顧一下,與 2 月時的指引相比,我們現在預期 2019 年將如何收官。以我們最初指引區間的中點計算,我們原先預期 2019 年營收為 84 億美元。目前營收指引的中點為 85.5 億美元,因此增加 1.5 億美元。營收增加中的 8,500 萬美元,來自對 LOE 資產預期營收約多 6,000 萬美元、收購 TRULANCE 帶來 5,500 萬美元,並被外匯(FX)不利變動 3,000 萬美元所抵銷。以上解釋了前 8,500 萬美元。其餘 6,500 萬美元的增加,來自我們基礎業務表現更佳,以及在部分業務中由 Project CORE 推動的毛到淨(gross-to-nets)優於我們原先預測。
The point of the story is that our original guidance for revenue on a constant currency basis and excluding the date uncertain LOEs was quite tight to how we expect to end up 2019. We're proud of the degree to which we've improved our forecast accuracy. That's back to you, Joe.
重點是:在固定匯率基礎上,並排除 LOE 日期不確定的項目後,我們最初的營收指引與我們目前預期的 2019 年結果相當貼近。我們為預測準確度提升的程度感到自豪。交回給你,Joe。
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
Thank you, Paul. Let's go through some of the highlights in our B+ L/International segment, the important takeaway from Slide #14. This segment delivered its 12th consecutive quarter of organic growth, up 5% versus last year, as you can see on the chart.
謝謝你,Paul。讓我們回顧一下 B+L/International(博士倫/國際)事業部的一些重點,也就是第 14 張投影片的重要結論。如圖表所示,該事業部實現連續第 12 個季度的有機成長,較去年成長 5%。
Turning now to Slide 15. Global Vision Care had a great quarter, up 6% organically, driven by the performance across Biotrue ONEday, up 22% and Ultra, up 25% as well as the AQUALOX launch. We launched the Ultra Multi Focal lenses for astigmatism in the U.S. in mid-June. These lenses offer consumers seamless transitions between distances from near to far and in between, and if surveyed, our patients using Ultra Multi Focal lenses, 92% agree that they are comfortable throughout the day, and 4 out of 5 patients surveyed preferred Bausch & Lomb Ultra Multi Focal over their previous method of vision correction.
接著看第 15 張投影片。全球視力保健本季表現出色,有機成長 6%,主要由 Biotrue ONEday(成長 22%)與 Ultra(也成長 25%)的表現,以及 AQUALOX 上市所帶動。我們於 6 月中旬在美國推出適用於散光的 Ultra Multi Focal 多焦點鏡片。這些鏡片可讓消費者在近距離、遠距離及其間距離之間順暢切換;在受訪者中,使用 Ultra Multi Focal 鏡片的患者有 92% 同意其全天配戴舒適,且受訪患者中有五分之四更偏好 Bausch & Lomb Ultra Multi Focal,而非其先前的視力矯正方式。
On Slide 16, LUMIFY continues to outpace expectations, having achieved a weekly market share of approximately 43%, as you can see from the chart on the right. Third quarter reported revenue of $21 million, grew by 91% compared to the second quarter.
在第 16 張投影片,LUMIFY 持續超出預期,如右側圖表所示,其每週市占率約達 43%。第三季公告營收為 2,100 萬美元,較第二季成長 91%。
LUMIFY is now the #1 eye care UPC in the United States and the #1 physician recommended product in the redness reliever category. E-commerce continues to be an important channel for our Global Consumer products, as the third quarter Amazon data demonstrates with 65% growth compared to the third quarter of 2018.
LUMIFY 現已成為美國排名第 1 的眼部護理 UPC 產品,以及在消除眼紅(redness reliever)類別中醫師最推薦的第 1 名產品。電子商務持續是我們全球消費者產品的重要通路;第三季的 Amazon 數據顯示,較 2018 年第三季成長 65%。
Turning now to Slide 17 for an update on Salix. Organic revenue grew by 18% compared with the third quarter of 2018 and revenue exceeded $500 million for the second consecutive quarter, driven by the TRx XIFAXAN as well as other promoted brands, including RELISTOR and PLENVU. Since our Salix acquisition in 2015, revenues are tracking greater than 12%, as we've shown in the chart on the left.
接著看第 17 張投影片,更新 Salix 的進展。有機營收較 2018 年第三季成長 18%,且在 XIFAXAN 的 TRx 以及其他主推品牌(包括 RELISTOR 與 PLENVU)的帶動下,營收連續第二個季度超過 5 億美元。自 2015 年收購 Salix 以來,營收走勢維持在高於 12% 的水準,如左側圖表所示。
Since 2017, we've been making investments in Salix to drive this growth, including hiring 200 primary care sales reps to expand the commercial field force for XIFAXAN, increasing the focus on next-generation XIFAXAN formulations, acquiring TRULANCE and dolcanatide earlier this year, and entered into license agreements to develop and commercialize novel compounds to treat GI conditions.
自 2017 年以來,我們持續對 Salix 投資以推動成長,包括聘用 200 名基層醫療(primary care)業務代表以擴大 XIFAXAN 的商業銷售團隊、加大對下一代 XIFAXAN 劑型的投入、於今年稍早收購 TRULANCE 與 dolcanatide,並簽訂授權協議以開發並商業化用於治療腸胃道(GI)疾病的新型化合物。
Turning now to Slide 18. We've shown the overall quarterly trend since we've added the primary care team at the beginning of 2017 in the chart on the left. With respect to IBSD specifically, TRxs grew by 14% compared to the prior year quarter and to date. XIFAXAN accounts, though, for less than 10% of the IBSD prescriptions. So we believe there is a great opportunity to help more IBSD patients.
接著看第 18 張投影片。左側圖表顯示,自 2017 年初我們加入基層醫療團隊以來的整體季度趨勢。就 IBSD 而言,TRx 較去年同期以及年初至今均成長 14%。不過,XIFAXAN 的處方量僅占 IBSD 處方的不到 10%。因此,我們認為仍有很大的機會幫助更多 IBSD 患者。
Moving on to TRULANCE on the right. TRULANCE has generated reported revenue of $37 million since the acquisition and remains on track towards full year guidance of $55 million. TRx grew by 25% compared to the prior year quarter and by 10% versus the second quarter sequentially. Since the TRULANCE acquisition in the first quarter of 2019, our team has done a great job, improving the market access position for greater than 37 million lives. We've also increased reach and frequency of TRULANCE promotion to healthcare providers by more than 90%.
再看右側的 TRULANCE。自收購以來,TRULANCE 已貢獻公告營收 3,700 萬美元,並仍按計畫朝全年指引 5,500 萬美元邁進。TRx 較去年同期成長 25%,較第二季按季成長 10%。自 2019 年第一季收購 TRULANCE 以來,我們的團隊表現出色,將市場准入地位改善至覆蓋超過 3,700 萬人。我們也將對醫療照護提供者的 TRULANCE 推廣觸及率與頻次提高了 90% 以上。
Overall, we are pleased with TRULANCE progress in the IBSD category. And as we focus on reestablishing momentum for TRULANCE, we've prioritized our Salix portfolio. And as a result, we mutually agree with US WorldMeds to terminate our arrangement to co-promote LUCEMYRA effective September 30.
整體而言,我們對 TRULANCE 在 IBSD 類別的進展感到滿意。而在我們聚焦於重新建立 TRULANCE 的成長動能之際,我們已將 Salix 產品組合列為優先事項。因此,我們與 US WorldMeds 共同同意,自 9 月 30 日起終止雙方共同推廣 LUCEMYRA 的合作安排。
Moving on to Ortho Derm on Slide 19. While we reported a total segment organic revenue decline in the third quarter, the performance of Global Solta, our aesthetics business, has been outstanding, up 62% organically compared to the prior year quarter, driven by the strong launch of Thermage FLX in the Asia Pacific region.
接著看第 19 頁的 Ortho Derm。雖然我們在第三季回報該事業部整體有機營收下滑,但我們的醫美業務 Global Solta 表現非常亮眼,有機成長 62%(相較去年同期),主要受惠於 Thermage FLX 在亞太地區的強勁上市表現。
We've shown the quarterly growth on the chart on the right. Additional highlights include a strong DUOBRII launch, which I'll talk about in the next slide, SILIQ TRx growth of 65% compared to the third quarter of 2018, BRYHALI scripts also grew nicely, up 20% from second quarter, and we expanded our dermatology cash-pay prescription program, Dermatology.com to more than 9,000 Walgreens U.S. retail pharmacies, which will offer patients convenient access to our products at a predictable price.
我們在右側圖表中呈現了季度成長。其他重點包括:DUOBRII 強勁上市(我會在下一頁說明)、SILIQ 的 TRx 較 2018 年第三季成長 65%、BRYHALI 處方量也有不錯成長,較第二季上升 20%;此外,我們將皮膚科自費處方計畫 Dermatology.com 擴展至超過 9,000 家 Walgreens 美國零售藥局,讓病患能以可預期的價格更便利地取得我們的產品。
Finally, we continue to move new treatments through our pipeline. We filed an NDA for ARAZLO, an acne treatment and have a PDUFA date of December 22.
最後,我們持續推進研發管線中的新療法。我們已為 ARAZLO(痤瘡治療)提交 NDA,PDUFA 日期為 12 月 22 日。
On to Slide 20. Since the June launch, DUOBRII TRxs are tracking above the plan. Strong adoption by doctors, patients and managed care is driving weekly TRx growth. The chart on the left shows weekly TRx as compared to other dermatology launches. And as you can see from the data, the DUOBRII launch has been very strong in its first 4 months on the market, tracking right around 2,300 weekly TRxs.
接著看第 20 頁。自 6 月上市以來,DUOBRII 的 TRx 走勢高於計畫。醫師、病患與商業保險(managed care)的強勁採用,正推動每週 TRx 成長。左側圖表顯示每週 TRx 與其他皮膚科產品上市表現的比較。從數據可見,DUOBRII 在上市前 4 個月表現非常強勁,每週 TRx 約在 2,300 左右。
While the early launch has been supported by our couponing strategy, managed care is recognizing DUOBRII's potential and DUOBRII's quickly gaining commercial access. With the addition of DUOBRII to the CVS Caremark formula at the beginning of November, we are now at approximately 57% commercial access, as you can see in the chart on the right. We continue to believe there is an enormous opportunity for DUOBRII based on early data and remain very optimistic about DUOBRII's potential to improve the lives of patients with psoriasis.
雖然早期上市受惠於我們的折價券策略支持,但商業保險端正逐步認可 DUOBRII 的潛力,且 DUOBRII 正快速取得商業給付可及性。隨著 11 月初 DUOBRII 納入 CVS Caremark 處方集(formulary),我們目前的商業可及性約為 57%,如右側圖表所示。基於早期數據,我們仍相信 DUOBRII 具有龐大機會,並對其改善乾癬病患生活的潛力保持非常樂觀。
As we've shown on Slide 21, revenue of $525 million from new products accounts for approximately 10% of our core business revenue year-to-date as compared to only 2% and in 2017. We expect this number to continue growing, as we launch new products.
如第 21 頁所示,新產品帶來的 5.25 億美元營收,年初至今約占我們核心業務營收的 10%,相較之下 2017 年僅為 2%。隨著我們推出更多新產品,我們預期此數字將持續成長。
On to Slide 22. At the current run rate, 2019 revenue from our Significant Seven product is up 65% versus last year and tracking at approximately $265 million, down from our previous estimate of approximately $300 million.
接著看第 22 頁。以目前的執行速度來看,2019 年我們「Significant Seven」產品的營收較去年成長 65%,目前約為 2.65 億美元,低於我們先前約 3 億美元的估計。
Even though DUOBRII scripts have been better than expected, the expected approval and launch was delayed, we have been couponing to support the long-term DUOBRII opportunity.
儘管 DUOBRII 的處方量優於預期,但由於預期的核准與上市時程延後,我們採用折價券以支持 DUOBRII 的長期機會。
As you saw with the launch of XIFAXAN IBSD, early couponing is an effective way to initiate patient trials. As patients adopt DUOBRII, we expect couponing to fade and the realized selling price to improve. We continue to expect the Significant Seven annualized peak total revenues of over $1 billion by the end of 2022.
如同 XIFAXAN IBSD 上市時所見,早期提供折價券是啟動病患試用的有效方式。隨著病患逐步採用 DUOBRII,我們預期折價券力度將下降,而實現的銷售價格將改善。我們仍預期到 2022 年底,「Significant Seven」年化峰值總營收將超過 10 億美元。
Turning now to Slide 23, we show the progress of our late-stage new product pipeline in each of our 3 core business segments. In iHealth, we have a lot of pipeline activity. First, we're expecting to launch SiHy Daily lenses in the United States in late 2020. We are working on line extensions for LUMIFY with further clinical studies planned for 2020. Our Surgical business also has a number of late-stage pipeline products, including New Ophthalmic Viscosurgical Device and the enVista Trifocal and intraocular lenses.
接著看第 23 頁,我們展示三大核心業務部門各自的後期新產品研發管線進展。在 iHealth 方面,我們有大量管線活動。首先,我們預期於 2020 年底在美國推出 SiHy Daily 日拋鏡片。我們也在推進 LUMIFY 的產品線延伸,並規劃於 2020 年進行更多臨床研究。我們的手術業務亦有多項後期管線產品,包括新型眼科黏彈手術裝置(Ophthalmic Viscosurgical Device)以及 enVista 三焦點與人工水晶體。
Late last month, we announced an exclusive license for the commercialization of XIPERE in the U.S. and Canada. XIPERE is being developed as a treatment for macular edema associated with uveitis. And if approved by the FDA, XIPERE would be the first treatment for this condition. We expect the NDA to be resubmitted in the first quarter of 2020 and believe that FDA will review it within 6 months of resubmission.
上個月底,我們宣布取得 XIPERE 在美國與加拿大商業化的獨家授權。XIPERE 正被開發用於治療與葡萄膜炎相關的黃斑部水腫。若獲 FDA 核准,XIPERE 將成為此適應症的首個治療方案。我們預期 NDA 將於 2020 年第一季重新提交,並相信 FDA 會在重新提交後 6 個月內完成審查。
Moving on to Salix. We're expecting a readout for the cardiovascular Holter study of amiselimod around year-end. In addition, we are developing a number of new formulations and indications for Rifaximin that we've listed on the slide.
接著看 Salix。我們預期 amiselimod 的心血管 Holter 研究將在年底前後讀出結果。此外,我們也正在開發多項 Rifaximin 的新劑型與新適應症,已列於投影片中。
Interim analysis for the over hepatoencephalopathy study is expected in the first quarter of 2020.
針對肝性腦病變研究的期中分析,預計於 2020 年第一季進行。
In Ortho Derm, I mentioned the NDA submission for ARAZLO earlier, and we have a strong pipeline of other acne and atopic dermatitis treatments in Phase III.
在 Ortho Derm 方面,我先前提到已提交 ARAZLO 的 NDA;此外,我們在第三期也有一條強勁的其他痤瘡與異位性皮膚炎治療管線。
To wrap up on Slide 24. We continue to grow our existing business and invest in future growth drivers. We have a durable business, approximately 60%, which is not exposed to U.S. branded prescription pricing.
在第 24 頁做個總結。我們持續成長既有業務,並投資於未來的成長動能。我們擁有具韌性的業務結構,其中約 60% 不受美國品牌處方藥定價影響。
The third quarter was our seventh consecutive quarter of total company organic growth led by B+ L/International and Salix, and we expect a strong growth outlook for the next 3 years. We're continuing to invest in sustainable growth drivers. We are increasing R&D investment and continue to deliver new products, while also pursuing value-creating acquisition, partnerships and licensing opportunities.
第三季是我們全公司總體有機成長連續第七季,主要由 B+L/International 與 Salix 帶動,我們預期未來 3 年仍有強勁的成長展望。
And we've leveraged our investment for the XIFAXAN primary care sales force to now also promote TRULANCE.
此外,我們也運用對 XIFAXAN 基層醫療(primary care)銷售團隊的投資,讓該團隊現在也能推廣 TRULANCE。
Finally, we are consistently improving our balance sheet, having reduced debt as of September 30 by $8.5 billion since the first quarter of 2016. We have also successfully managed the maturity profile of our outstanding debt and produced strong cash flow from operations.
最後,我們持續改善資產負債表;截至 9 月 30 日,自 2016 年第一季以來我們已減少 85 億美元的負債。我們也成功管理未償債務的到期結構,並創造強勁的營運現金流。
For these reasons, we believe that our third quarter results demonstrate that Bausch Health is well positioned for long-term growth.
基於上述原因,我們認為第三季的業績顯示 Bausch Health 已具備良好條件,能實現長期成長。
With that, operator, let's open up the line for questions.
接下來,接線員,請開放電話線供提問。
Operator
Operator
(Operator Instructions) The first question comes from Chris Schott of JPMorgan.
(接線員指示) 第一個問題來自 JPMorgan 的 Chris Schott。
Christopher Thomas Schott - Senior Analyst
Christopher Thomas Schott - Senior Analyst
Congrats on the quarter. I guess, my first was on DUOBRII. Can you just talk a little bit more about how we should be thinking about gross to net dynamics for this product in the near term? So how long will this couponing strategy continue as well as any color in terms of where you see gross to net stabilizing longer-term as we translate this very healthy volume trend we're seeing, what that means from a revenue perspective? My second question was on gross margin upside. We've seen that throughout 2019, just a little more color in terms of what's driving that and how sustainable the upside is? So basically I'm trying to get to is, is the 73% a good number going forward? Does that go up or down? Or just any kind of pushes and pulls or should be thinking about that going forward.
恭喜本季表現。我想第一個問題是關於 DUOBRII。你能否再多談一些,我們在短期內應如何看待這個產品的 gross-to-net 動態?也就是說,這個折價券策略會持續多久?另外,從長期來看,當我們把目前看到的非常健康的量的趨勢轉化為營收時,你們預期 gross-to-net 大概會在什麼水準趨於穩定?第二個問題是關於毛利率上行空間。我們在 2019 年一路看到毛利率改善,能否再多提供一些驅動因素以及這種上行的可持續性?我基本上想了解的是,73% 這個數字未來是否是合理的水準?它會上升還是下降?或是未來有哪些拉抬與壓抑因素是我們應該納入考量的?
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
Chris, thank you for the question. I'll start with DUOBRII. Yes, we are really excited about what we see for the launch of DUOBRII in both the acceptance by physicians, patients and really -- how we're really making a difference in these lives of patients. Relative to the question, yes -- our couponing strategy is such that we want to encourage the opportunity for patients to give it a try. But if you look at what we've been able to do on our slide and looking at the overall market access acceptance, when we were talking last quarter, the acceptance or -- I'm sorry, I should say, the market access was about 30% coverage and then by September, it moved up to 38%, now it's up to 43%. And right now, we're at the beginning of the number, we're right about 57% commercial coverage. We think that's going to be a big help to us as improving the gross to net.
Chris,感謝你的提問。我先從 DUOBRII 談起。是的,我們對 DUOBRII 上市後所看到的情況感到非常振奮,無論是醫師與病患的接受度,以及——我們確實正在為這些病患的生活帶來改變。針對這個問題,是的——我們的折價券策略是希望鼓勵病患有機會先嘗試使用。但如果你看我們投影片上的成果,以及整體市場准入的接受度,上季我們提到時,准入覆蓋率約為 30%,到 9 月提升到 38%,現在已到 43%。而目前在這個數字的起點,我們的商業保險覆蓋率約為 57%。我們認為,隨著總收入到淨收入(gross-to-net)改善,這將對我們有很大幫助。
The summation question or comment, I would say, is that I would say that we expect to be more of a steady state gross to net, somewhere around 12 months, as we, at that point, approach what we think will be approximately 70%, 75% market access coverage.
總結這個問題或評論,我會說,我們預期在大約 12 個月左右,總收入到淨收入會更接近穩態(steady state),屆時我們將接近我們認為約 70%~75% 的市場准入覆蓋率。
So it takes about 12 months, I believe, as a general comment for products in the pharmaceutical industry, but it always depends on market access coverage.
所以一般而言,我認為製藥產業的產品大約需要 12 個月,但仍取決於市場准入覆蓋率。
The second question, I think you have is relative to gross margin, Paul, why don't you take that one?
第二個問題我想是關於毛利率,Paul,你來回答這題如何?
Paul S. Herendeen - Executive VP & CFO
Paul S. Herendeen - Executive VP & CFO
Yes, sure. First, I'm not going to guide the gross margin percentage for 2020, but just let's comment on how we've done in 2019, because I think it's pretty impressive. It's really a combination of 3 things. One is Project CORE, which is -- that I've talked about quite a bit already. Dennis Asharin and our supply chain team have been engaged in the supply chain efficiency initiatives since 2016 and boy, are we getting results there, and it is helping, for sure, drive our aggregate gross margin percentage in the right direction.
好的,當然。首先,我不會對 2020 年的毛利率百分比提供指引,但我們先評論一下 2019 年的表現,因為我認為相當令人印象深刻。這其實是 3 件事的綜合結果。第一是 CORE 專案(Project CORE),也就是——我之前已談過不少。Dennis Asharin 與我們的供應鏈團隊自 2016 年起就投入供應鏈效率提升計畫,成果非常顯著,確實有助於推動我們整體毛利率朝正確方向前進。
The second thing is mix. We do have a mix of businesses. Those businesses have different margins. And so that certainly comes into play. I actually called out in my prepared remarks, where mix was a helper and mix was working against us in our Q3 results. And so that plays a big role in how you forecast into 2020 and beyond.
第二個因素是產品組合(mix)。我們的業務組合多元。這些業務的毛利率各不相同。因此這當然會產生影響。我在事先準備的發言中也特別指出,在我們第三季的結果中,哪些時候組合是助力、哪些時候組合反而對我們不利。因此,在你對 2020 年及之後進行預測時,這會扮演很重要的角色。
And the last piece I want to mention is the wildcard of FX. We are a global company. We have manufacturing facilities around the world. We produce in currencies and then often, we'll sell those products in other markets where the -- they are denominated in a different currency. So it's a bit of a wildcard. I -- you saw that we -- our year-to-date, 73.2%, and we're guiding to circa 73% for this year. It bounces around a little bit. I mean, I'm not going to guide you for next year. I'll just say we've made great progress doing the fundamental things right we're supposed to do to keep that percentage as high as it can be. Mix and FX are very big factors.
最後一點我想提的是外匯(FX)這個不確定因素。我們是一家全球性公司。我們在世界各地都有製造設施。我們以某些貨幣進行生產,但往往會在其他市場銷售這些產品,而——其計價貨幣不同。所以這有點像不確定因素。你也看到我們年初至今是 73.2%,而我們對今年的指引約為 73%。它會有些微波動。我的意思是,我不會對明年提供指引。我只想說,我們在把該做的基本功做好方面已取得很大進展,以讓這個百分比盡可能維持在高位。產品組合與外匯是非常重要的因素。
Operator
Operator
The next question comes from Umer Raffat of Evercore.
下一個問題來自 Evercore 的 Umer Raffat。
Umer Raffat - Senior MD & Senior Analyst of Equity Research
Umer Raffat - Senior MD & Senior Analyst of Equity Research
Joe, there's been a lot of commentary on the Street on setting DUOBRII expectations, possibly as high as $2 billion plus. And I noticed your Slide 20 today in the deck is also doing some of those same non-apples-to-apples comparison, in my opinion, comparing DUOBRII versus novel biologics like DUPI. So my questions are, number one, A, Joe, are you comfortable with setting expectations at those types of numbers? And two, if you take the DUOBRII TRx this quarter, which is 24,000 and you multiply it by a net price of even $500, you get to something like $10 million in sales. Now granted there's a lot of free drug, but that should still at least be $5 million in sales or so. The fact that it was less than $4 million. I'm just curious how much free drug is in those TRx that people are comparing versus DUPI? And then finally, just curious why TRULANCE declined quarter-over-quarter. And it sounds like based on your guidance, Q4 might also not be much higher than the 2Q levels?
Joe,華爾街對 DUOBRII 的預期設定有很多評論,可能高到 20 億美元以上。而我注意到你今天簡報中的第 20 頁投影片,在我看來也做了一些類似的、並非完全可比的比較,把 DUOBRII 與像 DUPI 這樣的新型生物製劑相比。所以我的問題是,第一,A,Joe,你是否對把預期設定在那種數字感到自在?第二,如果你把本季 DUOBRII 的 TRx(總處方量)24,000 乘上一個即便只有 500 美元的淨價格,你會得到大約 1,000 萬美元的銷售額。當然有很多免費用藥,但那至少也應該有大約 500 萬美元左右的銷售額。但實際卻不到 400 萬美元。我只是好奇,在那些人拿來與 DUPI 比較的 TRx 裡,有多少是免費用藥?最後,也想請教為什麼 TRULANCE 季對季下滑。而且聽起來依照你們的指引,第四季可能也不會比第二季水準高多少?
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
Okay. So first, I'm not going to make any comments specifically on the long-term guidance of DUOBRII specifically to numbers, other than to say, we're really excited by what we're seeing. Because for the very first time, we have a product that you can treat patients who have psoriasis topically and you can treat them to clearance. Whereas previously, you had a limited duration of treatment. So we think it's really exciting what we see. Obviously, the prescription in the first 4 months, we think, have been very strong in terms of growth rate.
好的。首先,我不會就 DUOBRII 的長期指引、特別是具體數字做任何評論;我只能說,我們對目前看到的情況非常振奮。因為這是第一次,我們有一個產品可以用外用方式治療乾癬病患,並且能讓他們達到清除(clearance)。而在此之前,你的治療期間是有限的。所以我們認為我們看到的情況非常令人興奮。顯然,在前 4 個月的處方表現上,我們認為就成長率而言非常強勁。
We clearly just wanted to look at some of the other products that have been dermatology specific and compared the uptake of our product versus them. We're not trying to put numbers out specifically for the future. As I say where we think it's going to be an important part of our future Dermatology business and help us with the turnaround of the Dermatology business.
我們只是想看看其他一些皮膚科相關產品,並比較我們的產品與它們的導入速度(uptake)。我們並不是要對未來提出具體數字。如我所說,我們認為它將成為我們未來皮膚科業務的重要一環,並協助我們推動皮膚科業務的轉型復甦。
On the question of the gross to net, we absolutely acknowledge that initial first 9 months, 12 months, will be a lower growth to net than what we would normally see and what we'll see at the, call it, steady state, but the reality is, it really depends a lot on how successful we are gaining commercial access. We think the uptake in commercial access, market access has been very good, and we'll look to continue to do that going forward. So that's really all I can say on the DUOBRII side, relative to -- we're not going to put a specific number out in the plan for future.
關於總收入到淨收入(gross-to-net)這個問題,我們完全承認,最初的前 9 個月到 12 個月,gross-to-net 會比我們通常看到的、以及我們在所謂穩態時會看到的更低;但現實是,這在很大程度上取決於我們取得商業保險准入的成功程度。我們認為商業准入、市場准入的提升速度一直非常不錯,我們也會在未來持續推進。所以就 DUOBRII 這部分,我能說的大概就這些;至於——我們不會在未來計畫中提出一個具體數字。
On the question of TRULANCE. Yes, the TRULANCE quarter 2 revenue was higher. That was -- if you recall, we acquired the product out of a bankruptcy situation, and there was some stocking in the quarter 2. But if you look at really the measure of growth, prescriptions for TRULANCE quarter 3 versus quarter 2 was up 10%. So we clearly think that's one important metric. There was some noise on the stocking side. And then, of course, as you think about quarter 3, this year versus quarter 3 2018, we were up 25%.
關於 TRULANCE 的問題。是的,TRULANCE 第二季營收較高。那是——如果你還記得,我們是在破產情境下收購該產品,因此第二季有一些通路備貨(stocking)。但如果你看真正的成長衡量指標,TRULANCE 第三季相較第二季的處方量成長了 10%。所以我們顯然認為那是一個重要指標。備貨端有一些雜訊。此外,當你看今年第三季相較 2018 年第三季,我們成長了 25%。
So every metric we look at with TRULANCE gives us a lot of optimism for the future, and certainly in line with what we said with our full year guidance on the $55 million.
因此,我們從 TRULANCE 觀察到的每一項指標都讓我們對未來充滿樂觀,而且也確實符合我們在全年指引中所提到的 5,500 萬美元。
So pleased with TRULANCE, especially now that we've moved from 100 reps promoting it to 200 reps, now up to 500 reps. We think there's a great opportunity as we brought together the XIFAXAN and TRULANCE IBS opportunity to have what we believe is a best-in-class product in IBSD with XIFAXAN, and we believe a best-in-class label with the TRULANCE product for IBSD, a long way to go in terms of the performance there, but we think it's a great opportunity for us.
我們對 TRULANCE 非常滿意,尤其是現在我們已經從 100 位業務代表推廣提升到 200 位,現在更增加到 500 位業務代表。我們認為機會非常大,因為我們把 XIFAXAN 與 TRULANCE 在 IBS 的機會整合在一起;我們相信在 IBSD 領域,XIFAXAN 是同級最佳產品,而 TRULANCE 在 IBSD 的適應症標籤上也是同級最佳。就該產品的表現而言仍有很長的路要走,但我們認為這對我們而言是很好的機會。
Operator
Operator
The next question comes from Akash Tewari of Wolfe Research.
下一個問題來自 Wolfe Research 的 Akash Tewari。
Akash Tewari - Director of Equity Research & Senior Research Analyst
Akash Tewari - Director of Equity Research & Senior Research Analyst
So consensus has the Derm segment kind of growing at a steady clip. If you include Solta, you go from like around $560 million to close to $900 million by 2025. Can you give us a sense of how you expect this segment to grow internally? And would it be fair to say that consensus isn't really modeling uptake for your IDP pipeline products. So of IDP 120, 123, 126, which one of the products are you guys kind of internally most bullish about? And why? And then a bit maybe on XIFAXAN and the patent case, what is your -- you've talked about your willingness potentially to settle with Novartis. How do you feel their case is different if at all with Teva's? And with that in mind, would we -- would it be unreasonable to expect a settlement or anything sooner than the 2028 that Teva had settled for previously?
市場共識認為皮膚科(Derm)部門會以穩定的速度成長。如果把 Solta 納入,你們到 2025 年會從大約 5.6 億美元成長到接近 9 億美元。你們能否談談你們內部預期這個部門會如何成長?另外,是否可以說市場共識其實沒有把你們 IDP 研發管線產品的導入/放量(uptake)納入模型?也就是 IDP 120、123、126 之中,你們內部最看好哪一個產品?為什麼?再補充一點關於 XIFAXAN 與專利訴訟:你們談過可能願意與諾華(Novartis)和解。你們認為他們的案件與 Teva 的案件有何不同(如果有的話)?在此背景下,我們是否不應該期待在 Teva 先前和解所對應的 2028 年之前,就出現更早的和解或任何進展?
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
Okay. You asked quite a few questions there. I'm going to try to get them all, but if I miss any, please do remind me. First, starting out in Dermatology. We are really excited about our Dermatology business, as most evidenced by my comments relative to DUOBRII. We think DUOBRII is a game changer, relative to the ability to treat these patients topically and which is what most psoriasis patients are looking for is to treat their product treat topically.
好的。你問了不少問題。我會盡量全部回答;如果我漏了任何一題,請提醒我。先從皮膚科開始。我們對皮膚科業務非常興奮,最能體現在我剛才對 DUOBRII 的評論。我們認為 DUOBRII 是一個改變遊戲規則的產品,因為它能以外用方式治療這些病人,而多數乾癬患者所追求的就是外用治療。
We also believe it's a game changer because of the ability for patients to delay the need for biologics. And as you know that we did a study that for every patient that you delay the need for a biology or the use of a biologic, you can save a plan significant amount of dollars. My recollection is for a plan with 1 million lives, it's something in the order of $3 million to $5 million of savings for that plan on an annual basis.
我們也認為它之所以是改變遊戲規則的產品,是因為它能讓患者延後使用生物製劑的需求。如你所知,我們做過一項研究:每延後一位患者需要使用生物製劑(或使用生物製劑的時間),就能為保險計畫節省相當可觀的費用。我記得對於涵蓋 100 萬名被保險人的計畫而言,每年大約可節省 300 萬到 500 萬美元。
So clearly, that is the first comment in terms of the overall DUOBRII in Derm.
因此,這顯然是我們對皮膚科中 DUOBRII 的第一個重點評論。
I'm not going to make any comments about the outlook for -- specifically for our commentary other than to say that we do believe the Dermatology business has a significant upside from where we are today. We had to work our way through the LOEs. We believe most of that is behind us, as Paul mentioned. Now as we look, we have the growth opportunity, especially with DUOBRII, BRYHALI, SILIQ in the category.
除了表示我們確實相信皮膚科業務相較於目前水準仍有顯著上行空間之外,我不會特別就展望做更多評論。我們必須先度過專利到期(LOE)的影響。如 Paul 所提到的,我們相信大部分影響已經在我們身後。接下來我們看到成長機會,特別是在 DUOBRII、BRYHALI、SILIQ 這一類別中。
On the question of other products, certainly on the 1 -- IDP 120, that's a dual product for acne, 123 is the ARAZLO that we also talked about for -- that we filed and have a December PDUFA date. So clearly, that's something that we think also could be an exciting opportunity for us, once again, in acne.
至於其他產品的問題,當然,IDP 120 是一個用於痤瘡的雙重組合產品;123 則是我們也提過的 ARAZLO 相關項目——我們已經遞交申請,PDUFA 日期在 12 月。因此,這顯然也是我們認為在痤瘡領域可能令人振奮的機會。
And then 126 is a triple combination we have. So a lot of good opportunities for us for the future. We think that's what's going to build our Dermatology business going forward.
而 126 則是我們的一個三重組合產品。所以未來對我們而言有很多很好的機會。我們認為這些將會推動我們的皮膚科業務在未來持續成長。
I think the last question you had was on XIFAXAN IP. We think we have a very strong position. We did file suit against Sandoz on September 30. We believe that the 22 patents that we were originally had now was supplemented with 1 additional patent that we announced. We now have 23 patents. We believe we have a very strong position. There's important commentary on intellectual property. We know that the polymorph patents are very important to us, and the FDA has come out with guidance on how one would need to be shown to be bioequivalent.
我想你最後一個問題是關於 XIFAXAN 的智慧財產權(IP)。我們認為我們的立場非常強。我們已於 9 月 30 日對 Sandoz 提起訴訟。我們相信原本的 22 件專利,已再補充 1 件我們已公告的新增專利。目前共有 23 件專利。我們相信我們的立場非常強。在智慧財產權方面有一些重要的評論。我們知道多晶型(polymorph)專利對我們非常重要,而 FDA 也已發布指引,說明需要如何證明生體相等性(bioequivalent)。
We think that the differences in the absorption of the polymorph is a very important consideration and one that gives us -- based on our information, a very strong position to defend it, and we see nothing in the Sandoz filing that would give us reason to move off of that 20 28 days. So we feel very good about it. And obviously, we'll continue to try to work through with Sandoz but feel very strong about our 20 28 day.
我們認為多晶型吸收差異是一個非常重要的考量;根據我們掌握的資訊,這也讓我們在防禦上具有非常強的立場。我們在 Sandoz 的申請文件中沒有看到任何理由,會讓我們偏離 2028 年那個日期。因此我們感覺非常好。當然,我們會持續嘗試與 Sandoz 推進相關事宜,但我們對 2028 年那個日期的立場非常有信心。
Operator
Operator
The next question comes from Greg Gilbert of SunTrust.
下一個問題來自 SunTrust 的 Greg Gilbert。
Gregory B. Gilbert - Analyst
Gregory B. Gilbert - Analyst
First, Paul, I know you're not in the mood to give a lot of specifics about 2020, but hoping you could just at least highlight some of the pushes and pulls as you see them in '20? And as part of that, more of a qualitative question about, just maybe a little bit quantitative, but how much flexibility do you expect to have next year to consider extra curricular activities in BD, as you continue to emphasize deleveraging sort of 2020 versus how it has felt in '19 and previously?
首先,Paul,我知道你不太想提供太多關於 2020 年的具體細節,但希望你至少能概述一下你所看到的 2020 年的一些推力與拉力(利多與利空)?另外,作為其中一部分,這是一個偏質性的問題,也許帶一點量化:在你們持續強調去槓桿的情況下,你預期明年在商務開發(BD)方面,能有多少彈性去考慮一些額外的活動?相較於 2019 年以及更早之前,2020 年的感受會如何?
And then secondly, on XIFAXAN, there's a competitive launch coming in traveler's diarrhea. I know it's a tiny revenue contributor for XIFAXAN. But Joe, maybe you could talk about whether you're seeing or expect to see any signs in the contracting environment that, that is relevant, even though it's not a head-to-head sort of comparison to where the business lies?
第二個問題,關於 XIFAXAN:在旅遊者腹瀉(traveler's diarrhea)領域即將有競品上市。我知道這對 XIFAXAN 來說是很小的營收貢獻。但 Joe,也許你可以談談:即使這不是與你們主要業務所在領域的正面對決,你們是否在合約談判環境中看到、或預期會看到任何相關的跡象?
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
Ok, thanks...
好的,謝謝……
Paul S. Herendeen - Executive VP & CFO
Paul S. Herendeen - Executive VP & CFO
Yes. Sure. Let me start again, don't want to provide guidance for 2020, but there are some things that you should be able to take away from our commentary earlier today that help you start thinking about at least how we view 2020.
是的。當然。我先說明:我不想提供 2020 年的指引,但你們應該可以從我們今天稍早的評論中帶走一些重點,幫助你們開始思考至少我們如何看待 2020 年。
I mean I'll start with the B+ L/International segment. We are continuing to deliver solid kind of mid single-digit organic revenue growth in that B+ L/International segment, and we talked in the past how this business over time is kind of a mid maybe even a little better than mid single-digit performer or could expect to be. That is the majority of our revenue.
我先從 B+L/International(B+L/國際)部門談起。我們在該 B+L/國際部門持續交出穩健的中個位數(mid single-digit)的有機營收成長,而我們過去也談過,長期來看這個業務大致上是中個位數、甚至可能略優於中個位數的表現者,或可如此預期。
So as you're thinking about it, that piece, there's one growth driver. Second, I called out XIFAXAN, obviously, our largest individual asset and was pretty clear. I mean you can come up with your own volume expectation growth for volume in XIFAXAN for 2020 v '19, and we've said we get a couple of hundred basis points of, we think, of a pickup in price there. So you've got your largest franchise, which you're expecting to grow at an attractive rate into 2020 v '19.
因此,當你在思考這件事時,那一塊有一個成長驅動因素。第二,我提到 XIFAXAN,顯然是我們最大的單一資產,而且我講得很清楚。我的意思是,你可以自行推估 2020 年相較於 2019 年 XIFAXAN 的銷量成長預期,而我們也說過,我們認為價格方面會有幾百個基點的提升。所以你有你最大的產品線,預期在 2020 年相較於 2019 年以具吸引力的速度成長。
I called out the Derm, as we rebase it here in Q4, we expect the Medical Derm part of our business to return to a growth profile, that's on strength of the products that we've launched and are launching in the Medical Derm business. Part of that Ortho Derm segment, Solta has been growing very, very strong growth here in in '19 v '18.
我也提到皮膚科(Derm),當我們在第四季於此重新基期(rebase)後,我們預期業務中的醫學皮膚科(Medical Derm)部分將回到成長軌跡,這是基於我們已推出以及正在推出的醫學皮膚科產品的強勁表現。在那個醫美皮膚科(Ortho Derm)分部中,Solta 在 2019 年相較於 2018 年呈現非常、非常強勁的成長。
Do I expect it to grow at that same rate going forward, that will be hard to achieve, but I expect it to be kind of a strong grower. So there's a majority of our business, which you'd expect to be growing into 2020 versus '19.
我是否預期它未來仍能以同樣的速度成長?那會很難達成,但我預期它仍會是相當強勁的成長動能。因此,我們業務的大部分,你會預期在 2020 年相較於 2019 年仍會成長。
The flip side, the things that could be headwinds to headwinds for us there. I called out Glumetza. Glumetza was -- has been a great product for us. But as we had called out, I want to say we started talking about it at the end of Q1, giving people a heads up, keep an eye on. And it's been really good for us. But as that volume shifts into, what I'll call, far less profitable channels for us. That is going to be a year-over-year decline, and it's kind of a material MD&A item.
反過來看,可能對我們造成阻力的因素。我提到了 Glumetza。Glumetza 一直是我們很棒的產品。但如同我們先前提過的,我想我們在第一季末就開始談到它,提醒大家要留意。而它對我們一直表現很好。但隨著其銷量轉移到我所稱的、對我們而言獲利性低得多的通路。這將造成年度對年度的下滑,而且在 MD&A 中算是相當重要的一個項目。
The other thing I'd call out is we will -- when we provide our guidance for 2020, we'll, of course, update our LOE schedule. The next LOE of significance is something that I did speak about in talking about guidance, which is APRISO. We've moved that out to 1H '20. That comes January 1. It's different than if it comes June 29. So those are the things I'd be looking at when thinking about 2020 from a revenue perspective of the '19. I hope that helped.
另外我想指出的是,當我們提供 2020 年的財測指引時,當然也會更新我們的 LOE 時程表。下一個重要的 LOE 是我在談指引時也提到的,也就是 APRISO。我們已將其延後到 2020 年上半年。它在 1 月 1 日發生,和在 6 月 29 日發生,是不一樣的。因此,從 2019 年的營收角度思考 2020 年時,我會關注這些因素。希望這有幫助。
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
And on XIFAXAN, the competitive launch in traveler's diarrhea, we take every competitor very seriously. Having said that, the rifaximin product was approved approximately 1 year ago. And to date, we really haven't seen anything of consequence there yet. The only point I would add to that is that, for us, the traveler's diarrhea is less than 2% of our TRxs, so a very small portion of our business.
至於 XIFAXAN,在旅遊者腹瀉(traveler's diarrhea)適應症上的競品上市,我們非常嚴肅看待每一位競爭者。話雖如此,該 rifaximin 產品大約在 1 年前獲准。截至目前,我們在那方面其實還沒有看到任何實質影響。我唯一要補充的是,對我們而言,旅遊者腹瀉不到我們 TRx 的 2%,所以只占我們業務非常小的一部分。
And for the most part, managed care doesn't usually cover that. So I think it would be somewhat difficult to get too much contracting with that particular indication, but we'll obviously take it serious, and see what happens in the marketplace relative to the traveler's diarrhea indication.
而且多數情況下,管理式醫療(managed care)通常不會給付那個。所以我認為,要針對那個特定適應症做出太多合約談判可能會有些困難,但我們當然會嚴肅以對,並觀察市場上相對於旅遊者腹瀉適應症的發展。
Paul S. Herendeen - Executive VP & CFO
Paul S. Herendeen - Executive VP & CFO
Greg, I'm sorry, it's Paul again. I realized I skipped over your question regarding our flexibility to allocate free cash flow for business development opportunity. This year, I mean, I think early in the year, we were fortunate to be able to acquire the assets of Synergy and get the TRULANCE assets, then drop it into the Salix business. As I want to say, we would do that deal 100 out of 100 times. It was circa $190 million. And yes, I wish we could do one of those every quarter, but those sorts of transactions are not always available.
Greg,不好意思,我是 Paul,又來了。我意識到我略過了你關於我們在配置自由現金流以用於業務開發機會方面的彈性之問題。今年,我的意思是,我想在年初,我們很幸運能夠收購 Synergy 的資產並取得 TRULANCE 資產,然後把它納入 Salix 業務。我想說的是,這筆交易我們會 100 次裡做 100 次。金額約 1.9 億美元。是的,我希望每一季都能做一筆那樣的交易,但那類交易並不總是有。
As we look ahead to 2020 and beyond, we will continue to prioritize the use of our free cash flow to reduce our debt. I think we have reduced the quantum of our debt, and we are improving our leverage, but we continue to be a very highly levered company. And one that needs to work to bring our capital structure to something that is more reasonable for our company that is comprised the assets that we're comprised of. So we'll prioritize that.
展望 2020 年及以後,我們將持續優先運用自由現金流來降低負債。我認為我們已經降低了負債規模(quantum),也在改善槓桿比率,但我們仍是一家槓桿非常高的公司。而且我們需要努力把資本結構調整到對我們公司而言更合理的水準,考量到我們所擁有的資產組合。所以我們會優先處理這件事。
Now that said, if there are opportunities out there that fit dead center on top of our core areas of focus, that would be eye care, GI and medical derm, and we would certainly consider those things, and you should expect us to try to find -- trying to find opportunities where we could deploy capital in business development opportunities that would be value generative.
不過話說回來,如果市場上有機會正好完全符合我們的核心聚焦領域,也就是眼科照護、腸胃科(GI)以及醫學皮膚科(medical derm),我們當然會考慮;你也可以預期我們會嘗試尋找——持續尋找——能夠投入資本於業務開發、並能創造價值的機會。
Operator
Operator
The next question comes from David Amsellem of Piper Jaffray.
下一個問題來自 Piper Jaffray 的 David Amsellem。
David A. Amsellem - MD and Senior Research Analyst
David A. Amsellem - MD and Senior Research Analyst
Just a couple. So first, on DUOBRII, I wanted to come back to the topic of access. So you said 50 -- 57% covered commercial lives. So I wanted to get a sense of how much of that is hassle free, or maybe another way of asking the question is, what do the step throughs look like in terms of the covered lives? That's number one.
只有幾個問題。首先,關於 DUOBRII,我想回到可近性(access)這個主題。你說有 50——57% 的商業保險涵蓋人數(covered commercial lives)。我想了解其中有多少是無障礙(hassle free)的;或者換個方式問,在涵蓋人數中,所謂的 step through(逐步限制/階梯式要求)大概是什麼樣子?這是第一點。
And then on TRULANCE, I don't know if you're willing to cover this. Can you just talk about how we should envision steady state gross to net from that product? It seems like you've made some gains on contracting and reducing restrictions. So how does that affect [us] and once this statement it looks like longer term? And then lastly, real quick on dolcanatide. Do you have anything new to say about that? And where you may go in terms of the developing on the asset?
接著關於 TRULANCE,我不確定你是否願意談這個。你能否談談我們應如何想像該產品在穩態(steady state)下的毛額到淨額(gross-to-net)?看起來你們在合約談判以及降低限制方面取得了一些進展。那麼這對[我們]有何影響?以及從這個說法看起來,長期會是什麼樣子?最後很快問一下 dolcanatide。你對此有沒有任何新的說法?以及你們在該資產的開發方向上可能會怎麼走?
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
Yes, I'm going to try to get all of them, but let me start with DUOBRII. The question of what the step throughs look like for access. I think we've been very fortunate, as I said, we've continued to improve our access with DUOBRII moving from, as I said, when we're on this call, last quarter was 30%. Now we're up to 57%. A majority of that has improved specifically in the unrestricted for DUOBRII.
好的,我會盡量把問題都回答到,但先從 DUOBRII 開始。關於可近性方面 step through 的樣貌。我認為我們非常幸運,如我所說,我們持續改善 DUOBRII 的可近性;從我說的,上次電話會議時上一季是 30%。現在我們提升到 57%。其中大多數的改善,特別是在 DUOBRII 的無限制(unrestricted)方面。
We expect to have about 44% unrestricted and about 13% has some prior (inaudible) step throughs. But you can see the majority of the 57% is specifically an unrestricted access, which we think makes a lot of sense because, as I said before, it's the first time a patient could use a topical and treat to clearance versus what previously was limited on duration and because of the ability for us to potentially delay the need for biologics.
我們預期約有 44% 是無限制,約有 13% 需要某些事前(聽不清)step through。但你可以看到,57% 的大部分是明確的無限制可近性;我們認為這很合理,因為如我之前所說,這是第一次病人可以使用外用藥並治療至清除(treat to clearance),而過去在療程期間上有所限制,且因為我們有可能延後使用生物製劑(biologics)的需求。
On the second part of the question, TRULANCE, how do we envision the steady state of the product going forward? I think when we acquired it, we made the comment about what we were trying to accomplish. And I think we stayed to that comment. First thing we said we have to improve reach and frequency. And as I made comment on the call, we improved reach frequency by about 90% additional promotion behind our XIFAXAN primary care effort as well as what we have in gastroenterologist since we acquired it. So clearly, we're doing reach frequency.
關於問題的第二部分,TRULANCE,我們如何展望該產品未來的穩態表現?我認為在我們收購它時,我們曾評論過我們想要達成的目標。而我認為我們也一直遵循那個說法。我們說的第一件事是必須提升觸及率與推廣頻次。正如我在電話會議中提到的,自從我們收購後,我們在 XIFAXAN 基層醫療推廣以及我們在腸胃科醫師端既有的推廣基礎上,額外增加了約 90% 的觸及與頻次。所以很明顯,我們正在做到觸及與頻次。
On the second part of what we said we needed to improve the market access position, and we've done that. What specifically we've done is improve the availability of this product for about 37 million lives and by improving it, either we got additional formulary additions or we made it easier to use the product more, moving it more towards the unrestricted side of the equation.
第二部分是我們說需要改善市場准入地位,而我們已經做到了。具體而言,我們所做的是讓約 3,700 萬人的保險涵蓋能更容易取得這個產品;透過改善,我們要麼獲得了更多處方集(formulary)納入,要麼讓產品更容易使用,讓它在限制程度上更朝向不受限的一端移動。
So those are the things we've done with TRULANCE. And as we sit here today, our overall TRULANCE availability, unrestricted and restricted, is about 88%. So you can see we've made some really good progress there.
所以這些就是我們在 TRULANCE 上所做的事情。而截至今天,我們 TRULANCE 的整體可及性(不受限與受限合計)約為 88%。所以你可以看到,我們在這方面取得了非常好的進展。
And the third question you had with dolcanatide, we are continuing to evaluate dolcanatide. We do think it has some significant opportunities for us relative to us doing some additional preclinical work with molecules. At the very least, we clearly think it has a life cycle for us relative to improving TRULANCE, but we're going to look at other gastroenterology indications as well, as I said, through preclinical models. I think I got all your questions, David.
至於你第三個問題關於 dolcanatide,我們仍在持續評估 dolcanatide。我們確實認為,對於我們進一步以分子進行一些額外的臨床前工作而言,它對我們有一些重要機會。至少,我們清楚認為它在改善 TRULANCE 方面對我們具有產品生命週期的價值;但我們也會如我所說,透過臨床前模型,同時評估其他腸胃科適應症。David,我想我回答到你所有問題了。
Operator
Operator
The next question comes from Gary Nachman of BMO Capital Markets.
下一個問題來自 BMO Capital Markets 的 Gary Nachman。
Gary Jay Nachman - Analyst
Gary Jay Nachman - Analyst
First in B + L on the contact lens market. Just talk about how you've been able to gain share, particularly in the U.S.? And when will the Daily SiHy be ready to launch in the U.S.? And how much share could that potentially take? How will it be differentiated in the market? And then is Vyzulta still a major focus for the B + L team is Medicare where it needs to be? And when should we see this product accelerate? And then, Joe, on the cash-pay model for legacy Derm products, have those products gain traction yet? And how much should the expansion help in Walgreens that you talked about?
首先是 B + L 在隱形眼鏡市場方面。請談談你們如何能夠提升市占,特別是在美國?以及 Daily SiHy 何時會在美國準備好上市?它潛在可以拿下多少市占?它在市場上將如何差異化?另外,Vyzulta 對 B + L 團隊而言仍是主要重點嗎?Medicare 的狀況是否已達到需要的水準?我們何時應該會看到這個產品加速成長?然後,Joe,關於傳統 Derm 產品的自費(cash-pay)模式,那些產品是否已經開始獲得動能?以及你提到在 Walgreens 的擴張,應該會帶來多大幫助?
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
Okay. You got a lot there. I'm going to try to get them all in terms of, but if I missed anything, but please remind me. On the contact lens side, really, it's been the new innovation that we brought out, the new Ultra, the Biotrue, the Ultra Multi Focal, the Ultra Toric, that's been really the primary way because I mentioned to you, Biotrue was up 22%, Ultra was up 25% quarter versus a year ago.
好的。你問了很多。我會盡量全部回答;如果我漏了什麼,請提醒我。在隱形眼鏡方面,主要是我們推出的新創新產品:新的 Ultra、Biotrue、Ultra Multi Focal、Ultra Toric;這真的是主要方式,因為我提到過,Biotrue 較去年同期成長 22%,Ultra 較去年同期成長 25%。
So it really shows, I think, great performance by the team. I most certainly want to also recognize the team, Joe Gordon and his team have done some outstanding job, John Ferris as they've taken over this responsibility, and then Yang Yang on our international side has also done a great job on our business. So a lot of good efforts by the teams, really focusing on our new innovation and the opportunity for people to have better optics, more comfort and the ability to have access to new innovations, such as our multifocal for astigmatism.
所以這確實顯示出,我認為團隊表現非常出色。我也一定要表揚團隊:Joe Gordon 和他的團隊做得非常好,John Ferris 在接手這項責任後也表現出色;另外我們國際端的 Yang Yang 也在業務上做得很好。所以各團隊投入了很多努力,真正聚焦在我們的新創新,以及讓人們擁有更好的視覺品質、更舒適,並能取得新創新產品的機會,例如我們針對散光的多焦點產品。
On the question of the SiHy Daily, we said it's a second half of 2020. To date, in the United States, the U.S. SiHy percentage of market is about 12%, 13% of market, but it is growing significantly. And we believe we have an opportunity, once again, to bring some innovation into this marketplace with a new SiHy that we think is going to be very desirable for patients relative to the current existing SiHy products out in the market, which will help us with the growth of that product.
關於 SiHy Daily 的問題,我們說過會在 2020 年下半年。截至目前,在美國,美國 SiHy 的市場占比約為 12%、13%,但成長非常顯著。我們相信我們有機會再次把一些創新帶進這個市場,推出一款新的 SiHy;相較於目前市面上既有的 SiHy 產品,我們認為它會對患者非常有吸引力,並將有助於推動該產品的成長。
Vyzulta, is it still a focus? The answer is absolutely yes. If you look at our performance, the performance in the third quarter of 2019 was up 140% versus the third quarter of 2018. So I think you can clearly tell by that. The team is doing a good job with it and continuing to move that product forward for us as a company.
Vyzulta,仍然是重點嗎?答案是絕對是。如果你看我們的表現,2019 年第三季的表現較 2018 年第三季成長了 140%。所以我想你從這點可以很清楚看出來。團隊在這方面做得很好,並持續推動該產品,讓它為公司向前發展。
Last comment was the Dermatology.com, how much will the cash-pay program help us. We've been working very diligently. Bill Humphrey and his team has been working very diligently to ensure that as we got greater access, what we felt the problems that we can solve with Dermatology.com is to make sure that the doctors get the brand with the predictable access, and they get the product that they want and the formulation they want.
最後一個評論是關於 Dermatology.com,自費方案會對我們有多大幫助。我們一直非常努力在推進。Bill Humphrey 和他的團隊一直非常努力,確保在我們取得更大可及性的同時,我們認為 Dermatology.com 能解決的問題是:確保醫師能以可預期的可及性取得品牌,並取得他們想要的產品與他們想要的劑型。
And then, of course, for patients, that the patients have access in a network that means that they're going to get the products the doctor wanted. They're going to get the results that the doctor is expecting in the formulation that they're expecting at a very predictable price point.
當然,對患者而言,是讓患者能在一個網絡中取得產品,這意味著他們會拿到醫師想要的產品。他們會以非常可預期的價格點,拿到醫師所期待的效果、以及醫師所期待的劑型。
So that's what we expect is going to help us and having an additional 9,300 or so stores from Walgreens only makes it -- the model work even better. I think I got all your questions.
所以這就是我們預期能幫助我們的地方;而僅僅是從 Walgreens 增加約 9,300 家門市,只會讓這個模式運作得更好。我想我回答到你所有問題了。
Operator
Operator
The next question comes from Louise Chen of Cantor.
下一個問題來自 Cantor 的 Louise Chen。
Louise Alesandra Chen - Senior Research Analyst & MD
Louise Alesandra Chen - Senior Research Analyst & MD
First question I had for you is if you could comment more on the gross to net for the third quarter of '19? And the second question I want to ask you was as you move through this growth phase between 2019 and 2020, how do you plan to achieve the sales EBITDA growth that you've forecasted as a CAGR over the next couple of years? And the last question I had was just how should we think about R&D spend as we enter 2020 and beyond?
我第一個問題是,你是否可以多評論一下 2019 年第三季的 gross-to-net?第二個問題是,當你在 2019 到 2020 年之間進入這個成長階段時,你計畫如何達成你所預測、未來幾年以 CAGR 計算的銷售與 EBITDA 成長?最後一個問題是,當我們進入 2020 年及之後,我們應該如何看待研發(R&D)支出?
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
Paul, why don't you take that first -- the growth 2019 question?
Paul,你要不要先回答第一個——關於 2019 年成長的問題?
Paul S. Herendeen - Executive VP & CFO
Paul S. Herendeen - Executive VP & CFO
Yes, sure. And the gross to net is a -- it's kind of a, I'll call it, a complicated thing. But if you look, the gross to net pickup that we observed in the quarter and, frankly, have observed year-to-date, there's been a theme for us over the last couple of years. And it's not something that just kind of happened in a vacuum. It's been the result of a lot of management focus. We implemented some improved processes, and I'll use product returns as an example, if I might.
好的,當然。而 gross-to-net 是——算是,我會說,是一個複雜的事情。但如果你看,我們在本季觀察到的 gross-to-net 改善,而且坦白說,年初至今也觀察到,這在過去幾年一直是我們的一個主題。而這不是那種在真空中突然發生的事情。這是大量管理層聚焦的結果。我們導入了一些改善流程;如果可以的話,我用產品退貨作為一個例子。
I think it's worth spending a second on this. Year-to-date through September, the amount of product returns that we actually processed were $77 million less than we had in the same period in the prior year. That's a 30% reduction. So for the avoidance of doubt, our process return results in a credit against accounts receivable, meaning we're talking about cold hard cash here. So I'll repeat, $77 million favorable year-to-date versus 2018.
我認為值得花一點時間談談這件事。截至9月的年初至今,我們實際處理的產品退貨金額,比前一年同期少了7,700萬美元。這是30%的下降。因此為了避免疑義,我們的處理退貨會形成對應收帳款的貸項,也就是說,我們談的是實實在在的現金。所以我再重申一次:年初至今相較2018年,有7,700萬美元的有利差異。
So then why did process returns go down so much? It's because beginning back in the latter part of '16 and continuing even as we speak, we've more actively monitored and managed the channel inventories of our products. And what we're talking about here is mainly our brand and Rx businesses, I think we're talking about in the U.S. now, Salix, Neuro, Derm and Optho Rx, we tightened up our policies. We successfully challenged channel partners that may have been gaming us in the past. We've worked our channel inventories down, which is in and of itself, helpful. And significantly, we've changed our pricing policy, such as a large infrequent price increases are not part of our business model.
那麼,為什麼處理退貨會下降這麼多?原因是從2016年後期開始,並且直到現在仍在持續,我們更積極地監控並管理我們產品在通路端的庫存。我們這裡主要談的是我們的品牌與處方藥(Rx)業務,我想現在談的是美國市場:Salix、Neuro、Derm以及Optho Rx,我們收緊了政策。我們成功地對可能在過去利用漏洞操作我們的通路夥伴提出挑戰。我們已將通路庫存降下來,而這本身就很有幫助。而且很重要的是,我們改變了定價政策,例如大幅且不頻繁的漲價不再是我們的商業模式的一部分。
So we're working our way through the situation we started with, and we've made great progress, and that really resulted in measurable declines in the level of the process returns that you saw beginning in, say, 2018, and you're going to see this -- or you've seen it already in our 10-K and our 10-Q, yes, you look at the revenue recognition footnote, you can find information there.
因此,我們正在處理一開始面臨的狀況,並已取得很大進展;這確實帶來了可衡量的下降,反映在你從例如2018年開始看到的處理退貨水準下滑;而你將會看到這一點——或者你已經在我們的10-K與10-Q中看到了。
But as we've developed sufficient data to support an assumption that our future returns be less than we previously estimated and accrued, we changed both the amount by which we reduced gross sales for returns during that period, and we true-up the returns accrual to reflect a lower amount of returns that we now expect to process against previously sold product.
但當我們累積了足夠的數據,足以支持一項假設:未來退貨將低於我們先前估計並提列的水準時,我們就同時調整了兩件事:在該期間內,我們因退貨而自毛銷售額中扣減的金額;以及我們對退貨準備金進行調整(true-up),以反映我們現在預期將針對先前已售產品所處理的較低退貨金額。
So that first part, that reduction in the deduction amount continues on it as an increase in the average selling price for our impacted products. I'd call that out a little bit when I talked about XIFAXAN. And then the true-up of the accrual, that's a helper revenue in the current period, but does not repeat. And as such, it becomes a little bit more of a challenge when we're comparing this period from here forward. So I'll stop there.
因此第一部分,也就是扣減金額的降低,會持續反映為受影響產品平均售價的上升。我在談到XIFAXAN時有稍微提到這點。而準備金的調整(true-up)則是在當期帶來一次性的收入助益,但不會重複發生。因此,從現在往後在比較各期時,難度會稍微提高一些。我就先說到這裡。
I'll say it's not just returns, by the way, it's a whole host of things. I mean, it's rebates, it's how we manage our co-pay assistance cards and the overall trend of our gross net has been getting better some -- from '17 to '18 now year-to-date to '19, and that's something that's been a real helper for us so far.
順帶一提,不只是退貨,還有一整套因素。例如回扣(rebates)、我們如何管理自付額補助卡(co-pay assistance cards),以及我們整體毛利到淨額(gross-to-net)的趨勢,從2017到2018,再到2019年初至今,都有一些改善,而這到目前為止對我們是很大的助力。
And I think as we go forward, what it is, is it results in higher realized average net selling prices for those branded Rx products. That was sort of a long walk, but I hope it helps.
而我認為往後看,這會帶來那些品牌處方藥產品更高的已實現平均淨售價。這段說得有點長,但希望能有所幫助。
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
To the second part of your question, Louise, is about, I think our 3-year growth rates and CAGRs and what we're thinking about there. First and foremost, I'll remind everyone that we're looking at a revenue CAGR of 4% to 6% on a 3-year basis. And on EBITDA, 5% to 8% CAGR. So that's the mindset we have.
至於你問題的第二部分,Louise,我想是關於我們的三年成長率與複合年成長率(CAGR),以及我們對此的想法。首先我要提醒大家,我們以三年為基礎,目標是營收CAGR為4%到6%。而在EBITDA方面,CAGR為5%到8%。這就是我們的思維框架。
Relative to how we will do it? I mean, I think it comes down to just first, just look at what we've done, and then importantly, we move forward. If you look at what we've done, the B + L and the Salix business together have done very well for us. They now account for about 77% of our business. So clearly, that -- or 78% of our business. So it's clearly a large part of our business.
至於我們要如何達成?我認為關鍵在於:先看我們已經做到了什麼,然後更重要的是,往前推進。如果你看我們已經做的,B + L與Salix業務合在一起,對我們表現非常好。它們現在約占我們業務的77%。所以很明顯,那——或者說占我們業務的78%。因此它們顯然是我們業務中很大的一部分。
But by definition, the Derm business has not been there yet. We now think that we have the derm business at a point where with the success of a DUOBRII launch, BRYHALI launch continuing to grow, SILIQ, and then launching these new products, we think that turnaround is also going to help us with the future growth drivers. So yes, it's been so far fueled by the Salix and B + L, but we do think the Derm business is also now, as Paul mentioned in his comments, at a point where you can significantly contribute to our growth. So that part is clearly the Derm business is important.
但按定義來說,Derm業務到目前為止還沒有達到那樣的表現。我們現在認為,隨著DUOBRII成功上市、BRYHALI上市後持續成長、SILIQ,以及接下來推出這些新產品,我們已把皮膚科業務推進到一個階段,我們認為這個轉機也將成為未來成長動能的一部分。所以是的,到目前為止主要由Salix與B + L帶動,但我們也確實認為,正如Paul在他的評論中提到的,Derm業務現在也到了可以對我們成長做出顯著貢獻的階段。因此這部分很清楚:Derm業務很重要。
The second part of it is just new products across all of our business that. On the slide we showed on Page 21, new products in fiscal year '17 accounted for about 2% of our sales. Today, that's up to be about 10% of our revenue. So clearly, that's the second part, new products. And we expect to see that to continue to accelerate as we launch these opportunities.
第二部分就是我們各項業務的新產品。在我們於第21頁展示的投影片中,2017財年新產品約占我們銷售額的2%。今天,這已提升到約占我們營收的10%。所以很明顯,第二個因素就是新產品。而隨著我們推出這些機會,我們預期這個占比會持續加速提升。
And then the final thing, I'll just pick up on where Paul said, it's all about that project core in terms of making us more efficient, and that's a cost optimization, revenue enhancement project that has yielded very good returns for us, and we expect to see that continue going into the future, and that helps us both on the revenue side, but also on the EBITDA side.
最後一點,我想接續Paul提到的:關鍵在於Project Core,讓我們更有效率。
So those are the primary ways that we're going to work through. The final comment you have was about R&D spend. We did make significant investments in research and development in 2017, '18, now '19. I would look as we go forward, I'm not going to guide to it. But certainly, we think we'll continue to invest in R&D at slightly above our revenue growth rates, as we think about the future of where we are going with the product.
以上就是我們將推進的主要方式。你最後的評論是關於研發(R&D)支出。我們在2017、2018以及現在的2019都對研發做了重大投資。展望未來,我不會對此提供指引。但可以確定的是,當我們思考產品未來方向時,我們認為研發投資將會持續以略高於營收成長率的速度增加。
That concludes my comments there. Operator, I think I have time for 1 last question, please.
我在這部分的評論就到此結束。接線生,我想我還有時間再回答最後一個問題,謝謝。
Operator
Operator
And that question will come from David Risinger of Morgan Stanley.
下一個問題將由摩根士丹利(Morgan Stanley)的David Risinger提出。
David Reed Risinger - MD in Equity Research and United States Pharmaceuticals Analyst
David Reed Risinger - MD in Equity Research and United States Pharmaceuticals Analyst
So 3 questions, please. The first is, are there any formulary positioning changes of note for January 4, by Solta or SILIQ that could help their sales potential? Second, consensus isn't quite at the $1 billion level for the Significant Seven by the end of 2022. Are there any products you think consensus may be underappreciating besides DUOBRII?
請允許我問三個問題。第一個是:就1月4日而言,Solta或SILIQ在處方集(formulary)上的定位是否有任何值得注意的變動,可能有助於提升其銷售潛力?第二,市場共識預估到2022年底,「Significant Seven」的規模還不到10億美元。除了DUOBRII之外,是否還有任何產品是你認為市場共識可能低估的?
And then third, could you talk a little bit more on a bigger picture level about aesthetics market digital opportunities. It seems like consumers are increasingly receptive to purchasing products online and paying up for higher-value products and this seems like it could fit with your Ortho Derm direct-to-consumer initiative, but it's still not quite clear to me whether you're really there yet in terms of maximizing that potential for your Derm business?
第三,您能否從更宏觀的角度多談一些醫美市場的數位化機會。看起來消費者愈來愈願意在線上購買產品,並且願意為更高價值的產品支付溢價;這似乎與你們 Ortho Derm 的直面消費者(DTC)計畫相契合,但我仍不太清楚,就你們皮膚科業務而言,你們是否已經真正做到最大化這一潛力?
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
Okay. A lot of good questions. Maybe I'll try to take them one at a time here.
好的。很多很好的問題。也許我會在這裡嘗試逐一回答。
Vyzulta and SILIQ relative to the formulary positions and where are we today and how we continue to improve on that? We're very pleased with the success we've had with Vyzulta. Vyzulta right now is up to about 74% access -- commercial access and about somewhere around 30% on the Part D side. We know we are going to continue to work on that. I don't have anything specific to say about January contract, but I can simply say that our market access team has been doing a great job for all of our products, and we'll continue to look to renegotiate some of the positions we have with Vyzulta, both on the commercial side and on the Part D coverage side.
關於 Vyzulta 和 SILIQ 相對於處方集(formulary)位置的問題:我們目前處於什麼狀態,以及我們如何持續改善?我們對 Vyzulta 取得的成功感到非常滿意。Vyzulta 目前的可及性約為 74%——商業保險可及性,Part D 端大約在 30% 左右。我們知道會持續在這方面努力。我沒有任何關於一月合約的具體內容可說,但我可以說,我們的市場准入團隊在所有產品上都做得非常出色;我們也會持續尋求重新談判 Vyzulta 目前的一些位置,包含商業端以及 Part D 給付覆蓋端。
On the question of SILIQ. SILIQ is also right around the 78% on commercial coverage, less so on Part D, but it's much less of a Part D marketplace. So SILIQ has about, as I said, 78% coverage. We will continue to look to get better coverage there. But we think we've got pretty close to what we're looking for. In terms of what's going on.
關於 SILIQ 的問題。SILIQ 的商業保險覆蓋率也大約在 78% 左右,Part D 端則較少,但 Part D 本來就不是那麼大的市場。因此,正如我所說,SILIQ 約有 78% 的覆蓋。我們會持續爭取更好的覆蓋。但我們認為已經相當接近我們想要達到的水準。就目前的情況而言。
On the question -- second part of your question was on Significant Seven. We do think there are some upside. We mentioned DUOBRII clearly is one of the products that we think is a very significant opportunity for us. Beyond that, the other products we think are performing better than people expect is LUMIFY, RELISTOR, and we clearly think the SiHy Daily is a good opportunity. So those would be the ones that -- I don't want to comment specifically on any consensus model, but ones that we feel have a good opportunity for the future.
第二部分的問題是關於「Significant Seven」。我們確實認為還有一些上行空間。我們提到 DUOBRII 顯然是我們認為非常重要的一個機會產品。除此之外,我們認為表現優於外界預期的其他產品包括 LUMIFY、RELISTOR,而且我們也明確認為 SiHy Daily 是一個很好的機會。所以這些就是——我不想針對任何共識模型做具體評論——但我們認為未來具有良好機會的項目。
On the aesthetics market opportunity. Clearly, our -- what we're doing there is exactly what we commented before about dermatology.com and the Solta business. As we put those 2 businesses together, we think we've got the right prescription for the future. Some patients, especially with the treatment of acne, are just looking to get a cash-pay option, where the cash-pay option is not that much different than what they pay on a co-pay. So that's clearly one side.
關於醫美市場機會。很明顯,我們在那裡所做的,正如我們先前對 dermatology.com 與 Solta 業務所評論的一樣。當我們把這兩項業務結合起來時,我們認為我們已經為未來找到了正確的配方。有些病患,特別是在痤瘡治療方面,只是希望有一個自費(cash-pay)選項,而這個自費選項與他們支付的自付額(co-pay)差異並不大。所以這顯然是一個面向。
On the aesthetics business, I think the results of Solta and Tom Hart and what he's done there to speak for themselves, being up 62%. Clearly, they have done just an outstanding job. And our expectations is that we have a great opportunity for the future because, yes, it's doing really well in Asia. Yes, it's doing well here in the United States, but there's a European opportunity that, as Paul mentioned, we're investing in for the future. So we feel very good about the opportunities we see with aesthetics and specifically, both on the Solta side, but also what we're doing on cash pay, as we solve problems for patients that are looking for predictable access and a predictable price point, we think our cash-pay model will do exactly that.
在醫美業務方面,我認為 Solta 的成果、Tom Hart 以及他在那裡所做的一切,已經不言自明,成長達 62%。很明顯,他們做得非常出色。我們的預期是,未來我們有很大的機會,因為,是的,它在亞洲表現非常好。是的,它在美國也表現良好,但在歐洲仍有一個機會,正如 Paul 所提到的,我們正在為未來進行投資。因此,我們對醫美領域所看到的機會感到非常樂觀;具體而言,不僅是 Solta 端,還包括我們在自費支付方面所做的事——當我們為尋求可預期可及性與可預期價格點的病患解決問題時,我們認為我們的自費模式正好能做到這一點。
Operator, that concludes what we wanted to come today. I thank everyone for joining us and look forward to having more conversations in the future. Thank you. Have a great day, everyone.
接線員,以上就是我們今天想要說的內容。感謝各位的參與,也期待未來能有更多交流。謝謝。祝各位有美好的一天。
Operator
Operator
Thank you for attending today's presentation. You may now disconnect.
感謝您參加今天的簡報。您現在可以斷線。